Preclinical development of SIG-007 for treatment of Fabry disease

被引：0

作者：

Fluharty, Brian ^{[1
]}

Makino, Elina ^{[1
]}

Donovan, Marissa ^{[1
]}

Tietz, Drew ^{[1
]}

Pearson, Erika ^{[1
]}

Jansen, Lauren ^{[1
]}

Barney, Lauren ^{[1
]}

Sewell, Jared ^{[1
]}

Huang, Janet ^{[1
]}

Corzo, Deya ^{[1
]}

Moller, David ^{[1
]}

Peritt, David ^{[1
]}

Vivaldi, Rogerio ^{[1
]}

机构：

[1] Sigilon Therapeut, Cambridge, MA USA

来源：

关键词：

D O I：

10.1016/j.ymgme.2019.11.130

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

121

引用

页码：S57 / S57

页数：1

共 50 条

[21] Fabry disease. Diagnosis and treatment
Ueceyler, N.
Sommer, C.
SCHMERZ, 2012, 26 (05): : 609 - 618
[22] Management of Fabry Disease with Agalsidase Treatment
Pintos-Morell, Guillem
Lidove, Olivier
Mehta, Atul
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 953 - 963
[23] THE EFFECT OF PHLEBOTOMY AS A TREATMENT OF FABRY DISEASE
BEUTLER, E
WESTWOOD, B
DALE, GL
BIOCHEMICAL MEDICINE, 1983, 30 (03): : 363 - 368
[24] Targeted nanoliposomes for the treatment of Fabry disease
不详
MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S17 - S17
[25] Fabry Disease: The Current Treatment Landscape
Lenders, Malte
Brand, Eva
DRUGS, 2021, 81 (06) : 635 - 645
[26] Fabry disease: genetics, pathology, and treatment
Bernardes, Thaiza Passaglia
Foresto, Renato Demarchi
Kirsztajn, Gianna Mastroianni
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 : S10 - S16
[27] Current Treatment Trends in Fabry Disease
Linthorst, Gabor
CLINICAL THERAPEUTICS, 2009, 31 : S17 - S18
[28] Treatment of Anderson-Fabry Disease
Simonetta, Irene
Tuttolomondo, Antonino
Daidone, Mario
Miceli, Salvatore
Pinto, Antonio
CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (40) : 5089 - 5099
[29] Fabry Disease: The Current Treatment Landscape
Malte Lenders
Eva Brand
Drugs, 2021, 81 : 635 - 645
[30] Early detection and treatment of Fabry disease
Breunig, Frank
CLINICAL THERAPEUTICS, 2008, 30 : S45 - S45